# A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Source: https://onco.cc/trials/nct04219254/  
OnCo record `nct04219254` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of BI1206 in advanced solid tumours, run by BioInvent International AB, now recruiting.

## Summary

A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04219254 by BioInvent International AB, with 197 participants planned, started 2020-06-29 and due to reach its primary completion in 2027-11. Interventions recorded: BI1206.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04219254
- Phase: 1/2
- Setting: A Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
- Sponsor: BioInvent International AB
- Enrolled: 197

## Sources

- ClinicalTrials.gov NCT04219254: https://clinicaltrials.gov/study/NCT04219254

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [BioInvent International](https://onco.cc/companies/bioinvent-international/), [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct04219254.json